Signaturefd LLC Acquires 243 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Signaturefd LLC increased its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 12.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,146 shares of the medical equipment provider’s stock after acquiring an additional 243 shares during the quarter. Signaturefd LLC’s holdings in Zimmer Biomet were worth $261,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Schechter Investment Advisors LLC raised its holdings in shares of Zimmer Biomet by 21.6% during the third quarter. Schechter Investment Advisors LLC now owns 4,241 shares of the medical equipment provider’s stock valued at $476,000 after purchasing an additional 752 shares during the period. Atria Wealth Solutions Inc. boosted its holdings in Zimmer Biomet by 5.9% in the third quarter. Atria Wealth Solutions Inc. now owns 20,566 shares of the medical equipment provider’s stock worth $2,312,000 after acquiring an additional 1,144 shares in the last quarter. International Assets Investment Management LLC grew its stake in Zimmer Biomet by 11,244.9% in the fourth quarter. International Assets Investment Management LLC now owns 66,935 shares of the medical equipment provider’s stock valued at $8,146,000 after acquiring an additional 66,345 shares during the period. Amalgamated Bank increased its holdings in shares of Zimmer Biomet by 3.0% during the third quarter. Amalgamated Bank now owns 56,166 shares of the medical equipment provider’s stock valued at $6,303,000 after acquiring an additional 1,631 shares in the last quarter. Finally, Sequoia Financial Advisors LLC raised its position in shares of Zimmer Biomet by 37.5% during the fourth quarter. Sequoia Financial Advisors LLC now owns 155,965 shares of the medical equipment provider’s stock worth $18,981,000 after purchasing an additional 42,539 shares during the period. Institutional investors and hedge funds own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have commented on ZBH shares. Barclays boosted their price target on shares of Zimmer Biomet from $120.00 to $130.00 and gave the company an “underweight” rating in a research note on Monday, February 12th. JPMorgan Chase & Co. raised their price target on shares of Zimmer Biomet from $115.00 to $125.00 and gave the company a “neutral” rating in a research report on Friday, February 9th. Raymond James boosted their price objective on Zimmer Biomet from $133.00 to $137.00 and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. Evercore ISI raised their target price on Zimmer Biomet from $125.00 to $130.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. Finally, Citigroup lifted their target price on Zimmer Biomet from $134.00 to $140.00 and gave the company a “neutral” rating in a research report on Wednesday, April 3rd. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $139.39.

Zimmer Biomet Price Performance

Shares of NYSE ZBH opened at $119.35 on Friday. The firm has a market cap of $24.52 billion, a price-to-earnings ratio of 24.41, a price-to-earnings-growth ratio of 2.20 and a beta of 1.01. The stock has a fifty day simple moving average of $125.98 and a two-hundred day simple moving average of $119.52. The company has a current ratio of 1.61, a quick ratio of 0.78 and a debt-to-equity ratio of 0.39. Zimmer Biomet Holdings, Inc. has a 1-year low of $102.00 and a 1-year high of $149.25.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 8th. The medical equipment provider reported $2.20 earnings per share for the quarter, topping the consensus estimate of $2.15 by $0.05. Zimmer Biomet had a return on equity of 12.79% and a net margin of 13.85%. The company had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.93 billion. During the same quarter in the prior year, the company earned $1.88 EPS. The firm’s quarterly revenue was up 6.3% compared to the same quarter last year. Analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.07 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Investors of record on Friday, March 29th will be issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.80%. The ex-dividend date is Wednesday, March 27th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 19.63%.

Insider Activity at Zimmer Biomet

In other Zimmer Biomet news, VP Chad F. Phipps sold 26,156 shares of the stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $128.62, for a total transaction of $3,364,184.72. Following the sale, the vice president now owns 44,145 shares in the company, valued at $5,677,929.90. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.95% of the stock is owned by company insiders.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.